• Product NameDDAH2 Conjugated Antibody
• Host SpeciesRabbit
• ClonalityMonoclonal
• Species ReactivityHu, Ms, Rt
• Immunogen DescriptionSynthetic peptide within Human DDAH2 aa 1-100
• ConjugatesBiotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
• Excitation EmissionAF350: 346nm/442nm
  AF405: 401nm/421nm
  AF488: 493nm/519nm
  AF555: 555nm/565nm
  AF594: 591nm/614nm
  AF647: 651nm/667nm
  AF680: 679nm/702nm
  AF750: 749nm/775nm
• Alternative Names    DDAH antibody
  DDAH II antibody
  DDAH-2 antibody
  DDAH2 antibody
  DDAH2_HUMAN antibody
  DDAHII antibody
  Dimethylargininase 2 antibody
  Dimethylargininase-2 antibody
  Dimethylarginine dimethylaminohydrolase 2 antibody
  Dimethylarginine dimethylaminohydrolase II antibody
  G6a antibody
  N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 antibody
  NG dimethylarginine dimethylamino hydrolase homolog antibody
  NG30 antibody
  OTTHUMP00000029307 antibody
  OTTHUMP00000029310 antibody
  OTTHUMP00000174488 antibody
  OTTHUMP00000174489 antibody
  Protein G6a antibody
  S phase protein antibody
  S-phase protein antibody
  
• Accession No. Swiss-Prot#:O95865
  
• UniprotO95865
• Gene ID23564;
• Calculated MW 30kDa
• Formulation 0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
• Storage Store at 4˚C in dark for 6 months

• Suggested Dilution:
  AF350 conjugated: most applications: 1: 50 - 1: 250
  AF405 conjugated: most applications: 1: 50 - 1: 250
  AF488 conjugated: most applications: 1: 50 - 1: 250
  AF555 conjugated: most applications: 1: 50 - 1: 250
  AF594 conjugated: most applications: 1: 50 - 1: 250
  AF647 conjugated: most applications: 1: 50 - 1: 250
  AF680 conjugated: most applications: 1: 50 - 1: 250
  AF750 conjugated: most applications: 1: 50 - 1: 250
  Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

DDAH, a dimethylarginine dimethylaminohydrolase, hydrolyzes dimethyl arginine (ADMA) and monomethyl arginine (MMA), both inhibitors of nitric oxide synthases, and may be involved in in-vivo modulation of nitric oxide production. Impairment of DDAH causes ADMA accumulation and a reduction in cGMP generation. DDAH II, the predominant DDAH isoform in endothelial cells, facilitates the induction of nitric oxide synthesis by all-trans-Retinoic acid (atRA). DDAH proteins are highly expressed in colon, kidney, stomach and liver tissues.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting